COX-2 inhibition: a possible role in the management of prostate cancer? অনুযায়ী Sooriakumaran, P, Langley, SE, Laing, R, Coley, H

A blinded, randomised controlled trial of neo-adjuvant Celecoxib in patients with localised prostate cancer অনুযায়ী Sooriakumaran, P, Langley, S, Laing, R, Coley, H, Fox, S, Eden, C

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma অনুযায়ী Pinato, D, Brown, M, Trousil, S, Aboagye, E, Beaumont, J, Zhang, H, Coley, H, Mauri, F, Sharma, R

A blinded, randomized controlled trial of neo-adjuvant celecoxib in patients with early prostate cancer. অনুযায়ী Sooriakumaran, P, Macanas-Pirard, P, Fox, S, Coley, H, Bucca, G, Lovell, D, Henderson, A, Smith, C, Langley, S, Laing, R

A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. অনুযায়ী Sooriakumaran, P, Macanas-Pirard, P, Bucca, G, Henderson, A, Langley, SE, Laing, R, Smith, C, Laing, E, Coley, H

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. অনুযায়ী Sooriakumaran, P, Coley, H, Fox, S, Macanas-Pirard, P, Lovell, D, Henderson, A, Eden, C, Miller, P, Langley, SE, Laing, R